Credits: Canva
An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.
One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.
Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.
The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.
The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.
Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”
The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.
Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.
The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.
Credits: Public Domain
Wegovy: The maker of the well-known weight-loss and diabetes drugs Wegovy and Ozempic has lowered the prices for most of its products. Novo Nordisk announced that the monthly cost for injectable Wegovy and Ozempic will now be reduced for people who buy the medicines directly from the company, through telehealth partners or at retail pharmacies. The only dose not included in the cut is the 2 mg version of Ozempic, which will stay at 499 dollars per month.
This move is expected to reshape how much patients spend on these popular weight-loss and diabetes medicines. Here is what the change means for regular users.
The company’s decision comes after pressure from the Trump administration, which urged Novo Nordisk and rival Eli Lilly to reduce prices on popular weight-loss and diabetes treatments. Earlier in November, President Donald Trump announced that Medicare would begin covering Novo’s Wegovy and Lilly’s Zepbound for millions of older adults. Both companies also agreed to sell discounted versions of the medications through a new federal direct-to-consumer platform called TrumpRx, expected to launch in 2026.
Novo Nordisk continues to face challenges from compounding pharmacies that sell cheaper, non-approved copies of semaglutide, the active ingredient used in Wegovy and Ozempic.
“As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them,” said Dave Moore, executive vice president at Novo Nordisk. He added that the American healthcare system includes different types of coverage and purchasing options, and the updated savings programs aim to give faster financial relief to people without insurance or those choosing to pay on their own, as reported by USA Today.
Novo Nordisk has introduced new, lower prices for most doses of its leading weight-loss and diabetes medicines, Wegovy and Ozempic. The standard monthly rate for these medications is now set at 349 dollars for customers purchasing through the drugmaker, telehealth services or retail pharmacies. For first-time users, the .25 mg and .5 mg doses are priced at 199 dollars per month during the first two months. This introductory offer remains available until March 31, 2026, according to USA Today.
Many people have found GLP-1 medications difficult to afford because they carry steep price tags and are not widely covered by insurance. Wegovy’s current list price is $1,349.
Coverage has grown, but only gradually. A Mercer survey showed that in 2024, 44 percent of large employers offered coverage for GLP-1 drugs for weight management, compared with 41 percent the year before. Insurers tend to approve these medicines more readily when they are prescribed for diabetes or health issues such as heart conditions or sleep apnea.
Both companies are also working on tablet forms of their injectable weight-loss drugs. Earlier this month, Trump said that the upcoming oral versions would be offered at $149 per month once they reach the market.
According to Moore, Novo expects the FDA to clear the Wegovy pill by late 2025, with availability planned for early 2026. Lilly has applied for priority review of its own oral drug, orforglipron. Novo is also awaiting the FDA’s priority review for a higher-dose injectable form of Wegovy.
Credits: Canva
With the aim of preventing and detecting cervical cancer among women in Kerala, Health Minister Veena George shared that the health department's campaign, ‘Aarogyam Anandam Akratham Arbutham,’ has seen participation from over 20 lakh people. Out of these, around 30,000 individuals underwent further examination, and cancer was confirmed in 84 of them. Additionally, 243 individuals showed pre-cancerous signs. By identifying and treating these early warning signs, the minister emphasized that cervical cancer can often be prevented.
Cervical cancer remains one of the major cancers affecting women, she noted. While multiple factors can contribute to its development, the primary cause is infection with the human papillomavirus (HPV). Research indicates that roughly 7.9% of women in Kerala are affected by cervical cancer. Early detection is key, as it allows treatment to proceed without serious complications. Screening facilities are available to help in early identification.
Cervical cancer develops in the cervix, the lower portion of the uterus. It is almost always linked to a long-lasting HPV infection, which can cause normal cells to change and grow uncontrollably. While the body often clears HPV naturally, persistent infection can lead to pre-cancerous cell changes. If these changes are left untreated, they may progress into invasive cancer.
Some common warning signs of cervical cancer include abnormal vaginal bleeding (between periods, after sexual intercourse, or post-menopause), unusual vaginal discharge (which may be watery, bloody, or foul-smelling), and pelvic pain. As the cancer advances, more severe symptoms such as swelling in the legs, ongoing fatigue, and problems with urination or bowel movements can develop, according to the National Cancer Institute.
Catching cervical cancer early is critical because it allows treatment to begin before the disease advances, significantly improving survival chances. Cervical cancer usually develops slowly and may not cause symptoms in the early stages, making regular screening vital.
Most cases of cervical cancer are caused by HPV, a sexually transmitted infection. HPV spreads through sexual contact—including vaginal, anal, or oral sex—and can lead to cancer. Many people contract HPV at some point without realizing it, as their immune system may fight it off naturally. However, if the infection persists, it can trigger changes in cervical cells that may become cancerous.
Early detection relies on routine screening tests such as the Pap test (Pap smear) and the HPV test, which can detect precancerous changes or high-risk HPV infections before cancer develops. If screening results are abnormal, a colposcopy with a biopsy may be conducted for a closer examination of the cervix.
The HPV vaccine protects against genital warts and the majority of cervical cancer cases. It also shields against cancers of the vagina, vulva, penis, or anus caused by HPV, as well as cancers of the mouth, throat, and head and neck linked to the virus.
The vaccine works by helping the body develop immunity to certain HPV strains, making it easier to fight off infection if exposed later.
India is expanding HPV vaccination to prevent cervical cancer, targeting girls aged 9–14 through school-based campaigns and incorporating the indigenously developed Cervavac into the National Immunization Program. The ideal age to start vaccination is 9–12 years, before sexual activity begins, though catch-up doses are allowed up to age 26. Some guidance even permits vaccination up to age 45. The government is preparing for a nationwide rollout, but final plans and vaccine supply are still being finalized.
Credits: Canva
Scientists and clinicians are cautioning the public not to mix two widely used over-the-counter medicines, warning that pairing them can put unnecessary strain on the body. Their appeal comes shortly after Donald Trump and Robert F Kennedy Jr made headlines with remarks about Tylenol and autism, a claim that experts have repeatedly dismissed.
The current concern is different. Physicians are asking people to avoid taking Tylenol and NyQuil together, even though they are sold for separate purposes. Tylenol is meant for general pain and fever, while NyQuil is marketed to ease cold and flu symptoms at night. Both contain acetaminophen, which means the doses can add up more quickly than people realize.
Dr Brynna Connor told Parade that many adults unintentionally take far more than the recommended daily amount. She explained that four thousand milligrams is the absolute upper limit for healthy adults, but she encourages most patients to stay well below three thousand. Going beyond that threshold, even briefly, can damage the liver. According to her, people often double up on acetaminophen without recognizing how fast it can lead to liver failure.
As per Healthline, the body can process acetaminophen safely, but only within a defined range. Exceeding it places stress on the liver, especially when multiple medications contain the same ingredient.
Dr Parth Bhavsar added that combining NyQuil with Benadryl can also lead to trouble. Both products include diphenhydramine, which may cause heavy drowsiness, slower breathing, confusion, dizziness, or difficulty urinating when taken together. He noted that these combinations can increase the risk of falls or memory lapses.
The advisories come months after Donald Trump and Robert F Kennedy Jr held a joint media briefing in which they suggested that Tylenol use during pregnancy might raise the likelihood of autism in newborns. Their statements drew widespread criticism from experts.
During the briefing, Trump struggled to pronounce “acetaminophen” and claimed the drug posed a “very increased risk of autism,” a statement that has not been supported by scientific research. A new analysis by researchers in the United Kingdom, Spain, and Australia reviewed nine major summaries of existing studies, including work Trump had referenced. Their conclusion was that there is no clear evidence linking paracetamol use in pregnancy to autism or ADHD.
The group also pointed out that many reviews had gaps in their methods or did not fully adjust for genetic and environmental factors. When those variables were accounted for, the suggested connection between Tylenol and autism weakened or disappeared.
Acetaminophen, known in many places as paracetamol and sold under names such as Tylenol and Panadol, is a common non-prescription medicine used to reduce fever and ease mild to moderate pain. It works as an analgesic and a fever reducer. It is different from drugs like ibuprofen because it does not address inflammation. As per the Food and Drug Administration.
The American College of Obstetricians and Gynecologists responded to the findings, saying the results were consistent with what the organization has long maintained. According to a spokesperson, available research does not show a causal link between responsible acetaminophen use in pregnancy and autism or other developmental conditions. In other words, the organization does not see enough evidence to support claims made by Trump or Kennedy.
© 2024 Bennett, Coleman & Company Limited